

GenCore version 5.1.4_p5_4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: March 10, 2003, 21:31:17 ; Search time 142.984 Seconds
(without alignments)
488.248 Million cell updates/sec

Title: us-09-913-524-34

Perfect score: 31

Sequence: 1 atcattgtcctctgtgctatgtccaact 31

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 1125999159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : N_Geneseq_101002.*

```
1: /SID$2/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.*
2: /SID$2/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.*
3: /SID$2/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.*
4: /SID$2/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.*
5: /SID$2/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.*
6: /SID$2/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.*
7: /SID$2/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.*
8: /SID$2/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.*
9: /SID$2/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.*
10: /SID$2/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.*
11: /SID$2/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.*
12: /SID$2/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.*
13: /SID$2/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.*
14: /SID$2/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.*
15: /SID$2/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.*
16: /SID$2/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.*
17: /SID$2/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.*
18: /SID$2/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.*
19: /SID$2/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.*
20: /SID$2/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.*
21: /SID$2/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.*
22: /SID$2/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT.*
23: /SID$2/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.*
24: /SID$2/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.*
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query	Score	Match	Length	DB	ID	Description
C 1	31	100.0	405	24	ABL64291		Stomach cancer rel
2	31	100.0	425	7	AAN60429		Sequence encoding
3	31	100.0	1620	22	AAH57530		Human pancreas cel
4	31	100.0	1630	8	AAN70315		Sequence encoding
5	31	100.0	1700	22	AAO60608		Angiotensin conver
6	31	100.0	1873	11	AAQ01648		BUF-3 gene for hum
7	31	100.0	4068	24	ABL62912		Breast cancer rela
8	31	100.0	4068	24	ABL63117		Breast cancer rela
9	31	100.0	4068	24	ABL64417		Stomach cancer rel

10	31	100.0	14416	22	AAO5491	Human reproductive
11	31	100.0	14416	23	ABL98344	Human testicular a
12	26.2	84.5	958	7	AAN60427	Sequence encoding
13	23	74.2	3588	8	AAN70317	Sequence encoding
14	21.4	69.0	1667	12	AAQ10890	Encodes Xenopus Bo
15	20.6	66.5	9662	22	AAO7086	Human reproductive
16	20.6	66.5	17705	22	AAO7085	Human reproductive
17	19.8	63.9	406	16	AAQ89258	BMP-6 encoding DNA
18	19.8	63.9	406	16	AAQ89258	Bone morphogenetic
19	19.8	63.9	497	20	AAV24032	cDNA encoding bone
20	19.8	63.9	497	20	AAV99382	Encodes C-terminal
21	19.8	63.9	894	13	AAQ23678	BMP-6 coding seque
22	19.8	63.9	894	14	AAQ37567	DNA encoding carbo
23	19.8	63.9	1350	22	AAH76483	BMP 7/6 glu nucleo
24	19.8	63.9	1353	22	AAH76484	BMP 7/6 myc nucleo
25	19.8	63.9	1362	22	AAH76481	BMP 4/6 glu nucleo
26	19.8	63.9	2385	23	AAH65056	DNA encoding novel
27	19.8	63.9	2385	23	AAH78659	DNA encoding novel
28	19.8	63.9	2385	23	AAH81638	DNA encoding novel
29	19.8	63.9	2471	23	AAH71026	DNA encoding novel
30	19.8	63.9	2923	11	AAQ06173	Human Bone Morphog
31	19.8	63.9	2923	13	AAQ32855	BMP6. Rattus ratt
32	19.8	63.9	2923	14	AAQ37568	Human BMP-6 coding
33	19.8	63.9	2923	14	AAQ41294	Human BMP-6 gene.
34	19.8	63.9	3184	23	AAH87074	DNA encoding novel
35	19.8	63.9	5651	21	AAH77516	Human ORFX ORF3071
36	19.8	63.9	5801	22	AAH22778	Human cDNA encodin
C 37	19.8	63.9	31169	22	AAH41761	Genomic sequence #
C 38	19.8	63.9	31169	22	AAH75191	Human immune/haema
C 39	19.8	63.9	31169	23	ABK44029	Genomic DNA encodi
40	19.6	63.2	167343	24	ABL64403	Stomach cancer rel
41	19.6	63.2	167343	24	ABL67239	Thyroid cancer rel
C 42	19	61.3	1548	19	AAV66850	Chlamydia 16S ribo
C 43	19	61.3	2493	23	AAH88122	DNA encoding novel
C 44	19	61.3	5741	12	AAQ14939	Bacterial amylase
45	18.8	60.6	99	16	AAQ82942	Partial coding seq

ALIGNMENTS

RESULT 1
ABL64291/c
ID ABL64291 standard; DNA: 405 BP.
XX AC
XX AC ABL64291;

DT 15-MAY-2002 (first entry)

XX Stomach cancer related gene sequence SEQ ID NO:2628.

DE Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
KW Stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
KW cytostatic; gene therapy; antineoplastic; Wilms's tumour; adenocarcinoma;
KW gene; ds.

OS Homo sapiens.

XX OS

XX WO200194629-A2.

PN 13-DEC-2001.

PD 30-MAY-2001; 2001WO-US10838.

XX 05-JUN-2000; 2000US-209473P.

XX 05-JUN-2000; 2000US-209531P.

PR 18-SEP-2000; 2000US-233133P.

PR 18-SEP-2000; 2000US-233617P.

PR 20-SEP-2000; 2000US-234009P.

PR 20-SEP-2000; 2000US-234034P.

PR 20-SEP-2000; 2000US-234052P.

PR 22-SEP-2000; 2000US-234509P.

PR 22-SEP-2000; 2000US-234567P.

PR 25-SEP-2000; 2000US-234923P.
 PR 25-SEP-2000; 2000US-234924P.
 PR 25-SEP-2000; 2000US-235077P.
 PR 25-SEP-2000; 2000US-235082P.
 PR 25-SEP-2000; 2000US-235134P.
 PR 25-SEP-2000; 2000US-235280P.
 PR 26-SEP-2000; 2000US-235637P.
 PR 26-SEP-2000; 2000US-235638P.
 PR 27-SEP-2000; 2000US-235711P.
 PR 27-SEP-2000; 2000US-235720P.
 PR 27-SEP-2000; 2000US-235840P.
 PR 27-SEP-2000; 2000US-235863P.
 PR 28-SEP-2000; 2000US-236028P.
 PR 28-SEP-2000; 2000US-236032P.
 PR 28-SEP-2000; 2000US-236033P.
 PR 28-SEP-2000; 2000US-236034P.
 PR 28-SEP-2000; 2000US-236109P.
 PR 28-SEP-2000; 2000US-236111P.
 PR 29-SEP-2000; 2000US-236842P.
 PR 29-SEP-2000; 2000US-236891P.
 PR 02-OCT-2000; 2000US-237172P.
 PR 02-OCT-2000; 2000US-237173P.
 PR 02-OCT-2000; 2000US-237278P.
 PR 02-OCT-2000; 2000US-237294P.
 PR 02-OCT-2000; 2000US-237295P.
 PR 02-OCT-2000; 2000US-237316P.
 PR 03-OCT-2000; 2000US-237425P.
 PR 03-OCT-2000; 2000US-237598P.
 PR 03-OCT-2000; 2000US-237604P.
 PR 03-OCT-2000; 2000US-237606P.
 PR 03-OCT-2000; 2000US-237608P.
 PR 01-NOV-2000; 2000US-244867P.
 PR 01-NOV-2000; 2000US-245084P.
 XX
 PA (AVAL-) AVALON PHARM.
 XX
 XX Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S;
 PI Soppet DR, Weaver Z;
 XX WPI: 2002-188264/24.
 XX
 PT Screening for anti-neoplastic agent involves exposing cells to a
 PT chemical agent to be tested for anti-neoplastic activity, and
 PT determining a change in expression of a gene of a signature gene set -
 XX
 XX Claim 1; SEQ ID 2628; 44pp; English.
 XX
 CC The present invention describes a method (M1) for screening for an
 CC anti-neoplastic agent. The method involves exposing cells to a chemical
 CC agent to be tested for anti-neoplastic activity, determining a change in
 CC expression of at least one gene (I) of a signature gene set, where (I)
 CC comprises a sequence (S) selected from 8447 sequences (given in ABL61664
 CC to ABL70110), or is at least 95% identical to (S), where a change in
 CC expression is indicative of anti-neoplastic activity. (I) has cytostatic
 CC activity and can be used in gene therapy. M1 can be used for screening
 CC an anti-neoplastic agent, and can be used for producing a product which
 CC is the data collected with respect to the anti-neoplastic agent as a
 CC result of M1, and the data is sufficient to convey the chemical
 CC structure and/or properties of the agent. M1 can be used in the
 CC treatment of cancer such as colon, breast, stomach, lung, thyroid,
 CC esophageal, ovarian, kidney, prostate or pancreatic cancer,
 CC adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer,
 CC infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine
 CC carcinoma, papillary carcinoma and Wilms' tumour.
 XX
 SQ Sequence 405 BP; 88 A; 97 C; 98 G; 121 T; 1 other;
 Query Match 100.0%; Score 31; DB 24; Length 405;
 Best Local Similarity 100.0%; Pred. No. 0.00069;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ATCATTGCTCCCTCTGGTATCATGCCAACT 31
 ||||||||||||||||||||||||||||||||

Db 384 ATCATTGCTCCCTCTGGTATCATGCCAACT 354
 RESULT 2
 AAN60429
 ID AAN60429 standard; cDNA; 425 BP.
 AC AAN60429;
 XX
 DT 26-JUN-1991 (first entry)
 XX
 XX Sequence encoding human inhibin B subunit.
 DE
 XX Hormone; inhibin agonist; antagonist; reproductive; gonad; ss.
 KW
 XX Homo sapiens.
 OS
 XX
 FH Key Location/Qualifiers
 FT CDS 1..42
 FT mat_peptide /*tag= a
 FT 43..393
 FT /*tag= b
 XX
 PN WO8606076-A.
 PD 23-OCT-1986.
 XX
 PF 14-APR-1986; 86WO-AU000097.
 XX
 PR 20-DEC-1985; 85AU-0003961.
 PR 18-APR-1985; 85AU-0000194.
 PR 06-SEP-1985; 85AU-0002320.
 PR 29-OCT-1985; 85AU-0003157.
 PR 19-DEC-1985; 85AU-0003960.
 PR 01-JAN-1986; 86AU-0059039.
 PR 02-APR-1987; 87AU-0071015.
 PR 05-MAY-1986; 86CN-0103459.
 XX
 PA (BIOT-) BIOTECHN AUSTRI PTY.
 PA (MONU) MONASH UNIV.
 PA (HENR) PRICE HENRY'S HOSPITAL.
 PA (SVIN) ST VINCENTS'S INST MED RE.
 XX
 PI Forage R, Stewart A, Robertson D, Dekretser DM;
 XX
 JR WPI: 1986-291647/44.
 DR P-PSDB; AAP60520.
 XX
 PT New polynucleotide sequences and recombinant DNA - encoding
 PT inhibin and synthetic peptides useful for affecting gonadal
 PT function
 XX
 PS Claim 8; Fig 8; 71pp; English.
 XX
 CC DNA encoding inhibin and inhibin or part, analogues, homologues or
 CC precursors thereof when produced by recombinant techniques are also
 CC claimed, as well as pharmaceutical compositions thereof. These may
 CC be used as an inhibin agonist, antagonist or for eliciting an
 CC antigenic response to affect gonadal function or reproductive
 CC physiology.
 XX
 SQ Sequence 425 BP; 103 A; 116 C; 115 G; 91 T; 0 other;
 Query Match 100.0%; Score 31; DB 7; Length 425;
 Best Local Similarity 100.0%; Pred. No. 0.00069;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ATCATTGCTCCCTCTGGTATCATGCCAACT 31
 ||||||||||||||||||||||||||||||||
 Db 127 ATCATTGCTCCCTCTGGTATCATGCCAACT 157
 RESULT 3

AAH57530
ID AAH57530 standard; cDNA; 1620 BP.
AC AAH57530;
XX 10-SEP-2001 (first entry)
XX Human pancreas cell specific cDNA sequence SEQ ID NO:370.
XX
XX Human; tissue specific; diagnosis; brain; heart; skeletal muscle;
XX lung; liver; uterus; ovary; stomach; intestine; kidney; pancreas; ss;
XX metabolic disease; developmental disease; cytostatic; immunomodulatory;
XX neuroprotective; gene therapy; cancer; immunopathology; neuropathology.
XX
XX Homo sapiens.
XX
XX NC200132927-A2.
XX
XX 10-MAY-2001.
XX
XX 02-NOV-2000; 2000WO-US30396.
XX
XX 04-NOV-1999; 99US-0163508.
XX
XX {INCY-} INCYTE GENOMICS INC.
XX
XX Sornasse T, Seilhamer JJ, Watson GA;
XX WPI: 2001-291057/30.
XX
XX New cell and tissue specific polynucleotides useful for diagnosis.
XX PT prognosis or monitoring of treatments for disorders where the gene is
XX PT associated with a cancer, immunopathology or neuropathology -
XX
XX Claim 1; Page 287-288; 327pp; English.
XX
XX AAH57161 to AAH57576 represent cell and tissue specific polynucleotide
XX sequences (I). (I) can have cytostatic, immunomodulatory and
XX neuroprotective activities, and can be used in gene therapy. (I) and
XX proteins (II) encoded by then are used in high throughput screening
XX assays to select DNA molecules, RNA molecules, peptide nucleic acids,
XX mimetics, peptides, proteins, agonists, antagonists, antibodies or
XX their fragments, immunoglobulins, inhibitors, drug compounds and
XX pharmaceutical agents. Expression of (I) in a sample indicates the
XX differentiation of embryonic stem cells into a tissue selected from
XX brain, heart, kidney, liver, lung, skeletal muscle or pancreatic
XX tissues. (I) and (II) are used to produce an expression profile that
XX defines a metabolic or developmental process, treatment, condition,
XX disease or disorder. The gene profile can be used for diagnosis,
XX prognosis or monitoring of treatments and for investigating a
XX predisposition to a disorder where the gene is associated with a
XX cancer, immunopathology or neuropathology.
XX
XX Sequence 1620 BP; 475 A; 377 C; 476 G; 291 T; 1 other;
XX
Query Match 100.0%; Score 31; DB 22; Length 1620;
Best Local Similarity 100.0%; Pred. No. 0.00086;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 1 ATCATGTGCTCCCTCGCTATCATGCCAACT 31
Db 1230 ATCATGTGCTCCCTCGCTATCATGCCAACT 1260
XX
RESULT 4
AA70315
ID AAN70315 standard; cDNA; 1630 BP.
XX
XX AAN70315;
XX
XX 09-APR-1991 (first entry)
XX
XX Sequence encoding human inhibin beta-chain precursor beta-A.

XX Fertility control; contraception; hormone; spermatogenesis; ss.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX CDS 37..320 /*tag= a
XX FT /product-signal sequence
XX CDS 321..1166 /*tag= b
XX FT /product-pro region
XX mat_peptide 1167..11517
XX /*tag= c
XX
XX EP222491-A.
XX
XX 20-MAY-1987.
XX
XX 02-OCT-1986; 86EP-0307586.
XX
XX 12-SEP-1986; 86US-0906729.
XX 03-OCT-1985; 85US-0783910.
XX 10-FEB-1986; 86US-0827710.
XX
XX (GETH) GENENTECH INC.
XX
XX Mason AJ, Seeburg PH;
XX
XX WPI: 1987-137512/20.
XX P-PSDB; AAF70203.
XX
XX Recombinant human or porcine inhibin or activin - used for
XX PT modulating clinical condition or reproductive physiology of
XX PT animals.
XX
XX Disclosure; Fig 8A; 48pp; English.
XX
XX A comps. comprising human or porcine inhibin which is completely
XX free of unidentified or porcine proteins is claimed. Also claimed
XX are non chromosomal DNA encoding inhibin-alpha or an inhibin-beta
XX chain. Sequencing of inhibin-encoding cDNA has led to the
XX identification of prodomain regions located N terminal to the
XX mature inhibin chains that represent coordinately expressed
XX biologically active polypeptides. The prodomain regions or
XX prodomain immunogens are useful in monitoring preproinhibin
XX processing in transformant cell culture or in experiments directed
XX at modulating the clinical cond. or reproductive physiology of
XX animals.
XX
XX Sequence 1630 BP; 472 A; 390 C; 466 G; 302 T; 0 other;
XX
Query Match 100.0%; Score 31; DB 8; Length 1630;
Best Local Similarity 100.0%; Pred. No. 0.00086;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 1 ATCATGTGCTCCCTCGCTATCATGCCAACT 31
Db 1251 ATCATGTGCTCCCTCGCTATCATGCCAACT 1281
XX
RESULT 5
AAS06008
ID AAS06008 standard; DNA; 1700 BP.
XX
XX AAS06008;
XX
XX 12-SEP-2001 (first entry)
XX
XX Angiotensin converting enzyme (ACEV) splice variant DNA #8.
XX
XX Angiotensin converting enzyme splice variant; ACEV; interleukin 6;
XX granulocyte colony stimulating factor receptor; glucagon; hypertrophy;
XX

KW platelet-derived endothelial cell growth factor; cardiovascular disease;
KW cellular tumour antigen P53; cyclin-dependent kinase inhibitor 1C; ds;
KW vasoactive intestinal polypeptide receptor 2; arteriosclerosis; cancer;
KW myocardial infarction; coronary arterial thrombosis; renal disease;
KW diabetic nephropathy; muscular disease; immune disorder; sarcoidosis;
KW multiple sclerosis; immune complex nephritis; deep vein thrombosis;
KW nonaroidotic pulmonary granulomatous disease; endothelial abnormality;
KW vascular disorder; asbestosis.
XX Homo sapiens.
XX WO200136632-A2.
XX 25-MAY-2001.
XX 17-NOV-2000; 2000WO-IL00766.
XX 17-NOV-1999; 99IL-0132978.
XX 10-DEC-1999; 99IL-0133455.
XX (COMP-) COMPUGEN LTD.
XX Levine Z, David A, Azar I, Khosravi R, Bernstein J;
XX WPI; 2001-336004/35.
XX P-PSDB; RAU02908.
XX Novel alternative splicing variants e.g. variant of angiotensin
XX converting enzyme (ACEV), useful in identifying candidate compounds
XX capable of binding to the variant and to detect anti-variant antibodies
XX .
XX Claim 1; Page 319; 519pp; English.
XX The sequence represents a DNA encoding an angiotensin converting enzyme
XX splice variant (ACEV) polypeptide. The polypeptides of the invention
XX include variants of granulocyte colony stimulating factor receptor,
XX glucagon, interleukin 6, platelet-derived endothelial cell growth factor,
XX cyclin-dependent kinase inhibitor 1C, cellular tumour antigen P53, and
XX vasoactive intestinal polypeptide receptor 2. The polypeptides and their
XX associated nucleic acids are useful for identification of variant
XX sequences and detection of candidate compounds capable of binding the
XX molecules. The sequences of the invention can be used in the treatment
XX and diagnosis of various disorders including cardiovascular diseases such
XX as arteriosclerosis, myocardial infarction and coronary arterial
XX thrombosis, renal diseases such as diabetic nephropathy, muscular
XX diseases such as hypertrophy, immune disorders such as immune complex
XX nephritis, multiple sclerosis, cancer, sarcoidosis, nonaroidotic
XX pulmonary granulomatous diseases such as asbestosis and vascular
XX pathologies involving an endothelial abnormality such as deep vein
XX thrombosis.
XX Sequence 1700 BP; 509 A; 387 C; 440 G; 362 T; 2 other;
Query Match 100.0%; Score 31; DB 22; Length 1700;
Best Local Similarity 100.0%; Pred. No. 0.00087;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ATCATGCTCCCTCGCTATCATGCCAACT 31
|||||
Db 820 ATCATGCTCCCTCGCTATCATGCCAACT 850
RESULT 6
AAQ01648
ID AAQ01648 standard; DNA; 1873 BP.
XX
XX AAQ01648;
XX 27-JUL-1990 (first entry)
XX BUF-3 gene for human differentiation inducing factor.
XX

KW BUF-3; dhfr; dihydrofolic acid reductase; differentiation.
XX Homo sapiens.
XX Location/Qualifiers
FH Key 119..11397
FT CDS /*tag= a
FT misc_RNA 983..1397
FT /*tag= b
FT /*label=BUF-3 subunit
XX JP02009388-A.
XX 12-JAN-1990.
XX 08-JUL-1988; 88JP-0170142.
XX 09-MAR-1988; 88JP-0055270.
XX (AJIN) AJINOMOTO KK.
XX WPI; 1990-055348/08.
XX P-PSDB; AAR05413.
XX Physiologically active protein prepn. -
XX by transforming plasmid having gene coding physiologically
XX active protein and gene of dihydrofolic acid reductase to hamster
XX ovary etc.
XX Example 1; Fig 1; 12pp; Japanese.
XX Gene may be expressed by transforming a dhfr negative strain of CHO cells
XX with an active BUF-3 gene and dhfr carrying vector. The BUF-3 gene is
XX a cell differentiating factor.
XX Sequence 1873 BP; 566 A; 431 C; 520 G; 356 T; 0 other;
Query Match 100.0%; Score 31; DB 11; Length 1873;
Best Local Similarity 100.0%; Pred. No. 0.00088;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ATCATGCTCCCTCGCTATCATGCCAACT 31
|||||
Db 1133 ATCATGCTCCCTCGCTATCATGCCAACT 1163
RESULT 7
ABL62912
ID ABL62912 standard; DNA; 4068 BP.
XX
XX ABL62912;
XX 15-MAY-2002 (first entry)
XX Breast cancer related gene sequence SEQ ID NO:1249.
XX Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
XX stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
XX cytostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;
XX gene; ds.
XX Homo sapiens.
XX OS
XX WO200194629-A2.
XX 13-DEC-2001.
XX 30-MAY-2001; 2001WO-US10838.
XX 05-JUN-2000; 2000US-209473P.
XX 05-JUN-2000; 2000US-209531P.
XX 18-SEP-2000; 2000US-23133P.
XX 18-SEP-2000; 2000US-233617P.


```

XA (AVAL-) AVALON PHARM.
XX
XX Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S;
PI Soppet DR, Weaver Z;
XX
XX WPI: 2002-188264/24.
XX
XX Screening for anti-neoplastic agent involves exposing cells to a
PT chemical agent to be tested for anti-neoplastic activity, and
PT determining a change in expression of a gene of a signature gene set -
XX
XX Claim 1; SEQ ID 1454; 44pp; English.
XX
XX The present invention describes a method (M1) for screening for an
CC anti-neoplastic agent. The method involves exposing cells to a chemical
CC agent to be tested for anti-neoplastic activity, determining a change in
CC expression of at least one gene (I) of a signature gene set, where (I)
CC comprises a sequence (S) selected from 8447 sequences (given in ABL61664
CC to ABL70110), or is at least 95% identical to (S), where a change in
CC expression is indicative of anti-neoplastic activity. (I) has cytostatic
CC activity and can be used in gene therapy. M1 can be used for screening
CC an anti-neoplastic agent, and can be used for producing a product which
CC is the data collected with respect to the anti-neoplastic agent as a
CC result of M1, and the data is sufficient to convey the chemical
CC structure and/or properties of the agent. M1 can be used in the
CC treatment of cancer such as colon, breast, stomach, lung, thyroid,
CC oesophageal, ovarian, kidney, prostate or pancreatic cancer,
CC adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer,
CC infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine
CC carcinoma, papillary carcinoma and Wilm's tumour.
XX
XX Sequence 4068 BP; 1291 A; 744 C; 893 G; 1140 T; 0 other;
SQ
Query Match 100.0%; Score 31; DB 24; Length 4068;
Best Local Similarity 100.0%; Pred. No. 0.001;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY I ATCATTCCTCCCTCTGGCTATCATGCCCACT 31
DB 1093 ATCATTCCTCCCTCTGGCTATCATGCCCACT 1123

RESULT 9
ABL64417
ID ABL64417 standard; DNA; 4068 BP.
XX
XX ABL64417;
AC
XX
XX 15-MAY-2002 (first entry)
XX
XX Stomach cancer related gene sequence SEQ ID NO:2754.
DE
XX Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
KW cytostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;
KW gene; ds.
XX
XX Homo sapiens.
OS
XX WO200194629-A2.
PN
XX 13-DEC-2001.
XX
XX 30-MAY-2001; 2001WO-US10838.
XX
XX 05-JUN-2000; 2000US-209473P.
PR
XX 05-JUN-2000; 2000US-209531P.
PR
XX 18-SEP-2000; 2000US-233133P.
PR
XX 18-SEP-2000; 2000US-233617P.
PR
XX 20-SEP-2000; 2000US-234009P.
PR
XX 20-SEP-2000; 2000US-234034P.
PR
XX 20-SEP-2000; 2000US-234052P.
PR

```

```

PR 22-SEP-2000; 2000US-234509P.
PR 22-SEP-2000; 2000US-234567P.
PR 25-SEP-2000; 2000US-234923P.
PR 25-SEP-2000; 2000US-234924P.
PR 25-SEP-2000; 2000US-235077P.
PR 25-SEP-2000; 2000US-235082P.
PR 25-SEP-2000; 2000US-235134P.
PR 25-SEP-2000; 2000US-235280P.
PR 26-SEP-2000; 2000US-235637P.
PR 26-SEP-2000; 2000US-235638P.
PR 27-SEP-2000; 2000US-235711P.
PR 27-SEP-2000; 2000US-235720P.
PR 27-SEP-2000; 2000US-235840P.
PR 27-SEP-2000; 2000US-235863P.
PR 28-SEP-2000; 2000US-236028P.
PR 28-SEP-2000; 2000US-236032P.
PR 28-SEP-2000; 2000US-236033P.
PR 28-SEP-2000; 2000US-236034P.
PR 28-SEP-2000; 2000US-236109P.
PR 28-SEP-2000; 2000US-236111P.
PR 29-SEP-2000; 2000US-236842P.
PR 29-SEP-2000; 2000US-236891P.
PR 02-OCT-2000; 2000US-237172P.
PR 02-OCT-2000; 2000US-237173P.
PR 02-OCT-2000; 2000US-237278P.
PR 02-OCT-2000; 2000US-237294P.
PR 02-OCT-2000; 2000US-237295P.
PR 02-OCT-2000; 2000US-237316P.
PR 03-OCT-2000; 2000US-237425P.
PR 03-OCT-2000; 2000US-237598P.
PR 03-OCT-2000; 2000US-237604P.
PR 03-OCT-2000; 2000US-237606P.
PR 03-OCT-2000; 2000US-237608P.
PR 01-NOV-2000; 2000US-244867P.
PR 01-NOV-2000; 2000US-245084P.
XX
XX (AVAL-) AVALON PHARM.
XX
XX Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S;
PI Soppet DR, Weaver Z;
XX
XX WPI: 2002-188264/24.
XX
XX Screening for anti-neoplastic agent involves exposing cells to a
PT chemical agent to be tested for anti-neoplastic activity, and
PT determining a change in expression of a gene of a signature gene set -
XX
XX Claim 1; SEQ ID 2754; 44pp; English.
XX
XX The present invention describes a method (M1) for screening for an
CC anti-neoplastic agent. The method involves exposing cells to a chemical
CC agent to be tested for anti-neoplastic activity, determining a change in
CC expression of at least one gene (I) of a signature gene set, where (I)
CC comprises a sequence (S) selected from 8447 sequences (given in ABL61664
CC to ABL70110), or is at least 95% identical to (S), where a change in
CC expression is indicative of anti-neoplastic activity. (I) has cytostatic
CC activity and can be used in gene therapy. M1 can be used for screening
CC an anti-neoplastic agent, and can be used for producing a product which
CC is the data collected with respect to the anti-neoplastic agent as a
CC result of M1, and the data is sufficient to convey the chemical
CC structure and/or properties of the agent. M1 can be used in the
CC treatment of cancer such as colon, breast, stomach, lung, thyroid,
CC oesophageal, ovarian, kidney, prostate or pancreatic cancer,
CC adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer,
CC infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine
CC carcinoma, papillary carcinoma and Wilm's tumour.
XX
XX Sequence 4068 BP; 1291 A; 744 C; 893 G; 1140 T; 0 other;
SQ
Query Match 100.0%; Score 31; DB 24; Length 4068;
Best Local Similarity 100.0%; Pred. No. 0.001;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```



```
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251388.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen CA, Barash SC, Ruben SM;
XX
XX WPI; 2001-465570/50.
XX
XX Isolated nucleic acid molecule encoding a reproductive system antigen
XX is used in preventing, treating or ameliorating a medical condition -
XX
XX Disclosure; SEQ ID NO 8179; 1297pp + Sequence Listing; English.
XX
XX The present invention provides the protein and coding sequences of a
XX number of human reproductive system related antigens. These can be used
XX in the prevention and treatment of reproductive system disorders,
XX including cancer. The present sequence is a genomic sequence encoding a
XX protein of the invention.
XX
XX Sequence 14416 BP; 4206 A; 3105 C; 3196 G; 3909 T; 0 other;
XX
XX Query Match 100.0%; Score 31; DB 22; Length 14416;
XX Best Local Similarity 100.0%; Pred. No. 0.0012;
XX Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 ATCATTGTCCTCTGGCTATCATGCCAACT 31
XX |||||||
Db 13179 ATCATTGTCCTCTGGCTATCATGCCAACT 13209

RESULT 11
ABL98344
ID ABL98344 standard; DNA; 14416 BP.
XX
XX ABL98344;
XX
XX 21-JUN-2002 (first entry)
XX
XX Human testicular antigen encoding DNA fragment SEQ ID NO: 2996.
XX
XX Human; testicular antigen; testes; cancer; metastasis; immune disorder;
XX reproductive system disorder; urinary system disorder; gene therapy;
XX cardiovascular disorder; respiratory disorder; neurological disorder;
XX gastrointestinal disease; infection; cytostatic; gene; ds.
XX
XX Homo sapiens.
XX
XX W0200155317-A2.
XX
XX 02-AUG-2001.
XX
XX 17-JAN-2001; 2001WO-US01329.
XX
XX 31-JAN-2000; 2000US-0179065.
XX 04-FEB-2000; 2000US-0180628.
XX 24-FEB-2000; 2000US-0184564.
XX 02-MAR-2000; 2000US-0186350.
XX 16-MAR-2000; 2000US-0189474.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
```


PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241121.
PR 20-OCT-2000; 2000US-0241175.
PR 20-OCT-2000; 2000US-0241185.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251899.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX
PT Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-483232/52.
XX
PT Nucleic acids encoding 973 human testicular antigen polypeptides,
PT useful for preventing, diagnosing and/or treating testicular cancer
XX
PS Disclosure; SEQ ID NO 2996; 766pp; English.
XX
XX The present invention provides the protein and coding sequences of 973
CC human testicular antigens, and fragments of their genomic sequences. The
CC sequences can be used in the treatment of cardiovascular, urinary system,

CC reproductive system, immune, respiratory, neurological and
CC gastrointestinal disorders, infections, and particularly cancer,
CC especially testicular cancers. The present sequence is a DNA encoding a
XX protein fragment of the invention.
SQ Sequence 14416 BP; 4206 A; 3105 C; 3196 G; 3909 T; 0 other;

Query Match 100.0%; Score 31; DB 23; Length 14416;
Best Local Similarity 100.0%; Pred. No. 0.0012;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ATCATTGCTCCCTGCTGCTATCATGCCAACT 31
Db 13179 ATCATTGCTCCCTGCTGCTATCATGCCAACT 13209

RESULT 12
AAN60427
ID AAN60427 standard; cDNA; 958 BP.
XX
XX AC AAN60427;
XX
XX 26-JUN-1991 (first entry)
XX
XX Sequence encoding bovine inhibin B subunit.
XX
XX Hormone; inhibin agonist; antagonist; reproductive; gonad; ss.
XX Bos taurus.
XX
XX Key Location/Qualifiers
FT CDS 1..516
FT /*tag= a
FT mat_peptide 517..867
FT /*tag= b
XX
XX WO8606076-A.
XX
XX PD 23-OCT-1986.
XX
XX 14-APR-1986; 86WO-AU000097.
XX
XX 20-DEC-1985; 85AU-0003961.
PR 18-APR-1985; 85AU-0000194.
PR 06-SEP-1985; 85AU-0002320.
PR 29-OCT-1985; 85AU-0003157.
PR 19-DEC-1985; 85AU-0003960.
PR 01-JAN-1986; 86AU-0059039.
PR 02-APR-1987; 87AU-0071015.
PR 05-MAY-1986; 86CN-0103459.
XX
XX (BIOT-) BIOTECHN AUSTR PTY.
PA (MONU) MONASH UNIV.
PA (HENR-) PRICE HENRY'S HOSPITAL.
PA (SVIN-) ST VINCENT'S S INST MED RE.
XX
XX Forage R, Stewart A, Robertson D, Dekretser DM;
XX
XX WPI; 1986-291647/44.
DR P-PSDB; AAP60518.
XX
XX New polynucleotide sequences and recombinant DNA - encoding
PT inhibin and synthetic peptides useful for affecting gonadal
PT function
XX
XX Claim 8; Fig 6; 71pp; English.
XX
XX DNA encoding inhibin and inhibin or part, analogues, homologues or
CC precursors thereof when produced by recombinant techniques are also
CC claimed, as well as pharmaceutical compositions thereof. These may
CC be used as an inhibin agonist, antagonist or eliciting an
CC antigenic response to affect gonadal function or reproductive
CC physiology.

```
XX SQ Sequence 958 BP; 242 A; 240 C; 302 G; 174 T; 0 other;
Query Match 84.5%; Score 26.2; DB 7; Length 958;
Best Local Similarity 90.3%; Pred. No. 0.094;
Matches 28; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 ATCATGTCCTCCTCGCTATCATGCCAACT 31
||||| ||||| ||||| ||||| ||||| |||||
Db 601 ATCATGTCCTCCTCGCTATCATGCCAACT 631

RESULT 13
AAN70317
ID AAN70317 standard; cDNA; 3588 BP.
XX
AC
XX
DT 09-APR-1991 (first entry)
XX
DE Sequence encoding porcine inhibin beta-chain precursor beta-A.
XX
KW Fertility control; contraception; hormone; spermatogenesis; ss.
XX
OS Sus scrofa domestica.
XX
FH Key Location/Qualifiers
CDS 34..957
/*tag= a
FT mat_peptide 958..1307
FT polyA_signal 3551..3556
/*tag= c
XX
PN EP222491-A.
XX
XX 20-MAY-1987.
XX
XX 02-OCT-1986; 86EP-0307586.
XX
PR 12-SEP-1986; 86US-0906729.
PR 03-OCT-1985; 85US-0783910.
PR 10-FEB-1986; 86US-0827710.
XX
PA (GETH ) GENENTECH INC.
XX
PI Mason AJ, Seeburg PH;
XX
DR WPI: 1987-137512/20.
DR P-PSDB; AAP70200.
XX
PT Recombinant human or porcine inhibin or activin - used for
PT modulating clinical condition or reproductive physiology of
PT animals.
XX
PS Disclosure; Fig 1B; 48pp; English.
XX
XX A compsn. comprising human or porcine inhibin which is completely
CC free of unidentified or porcine proteins is claimed. Also claimed
CC are non chromosomal DNA encoding inhibin-alpha or an inhibin-beta
CC chain. Sequencing of inhibin-encoding cDNA has led to the
CC identification of prodomain regions located N-terminal to the
CC mature inhibin chains that represent coordinately expressed
CC biologically active polypeptides. The prodomain regions or
CC prodomain immunogens are useful in monitoring preproinhibin
CC processing in transformant cell culture or in experiments directed
CC at modulating the clinical condn. or reproductive physiology of
CC animals.
XX
SQ Sequence 3588 BP; 881 A; 986 C; 998 G; 723 T; 0 other;
Query Match 74.2%; Score 23; DB 8; Length 3588;
```

```
Best Local Similarity 83.9%; Pred. No. 2.8;
Matches 26; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1 ATCATGTCCTCCTCGCTATCATGCCAACT 31
||||| ||||| ||||| ||||| ||||| |||||
Db 1042 ATCATGTCCTCCTCGCTATCATGCCAACT 1072

RESULT 14
AAQ10890
ID AAQ10890 standard; DNA; 1667 BP.
XX
AC AAQ10890;
XX
DT 13-MAY-1991 (first entry)
XX
DE Encodes Xenopus Bone Morphogenetic Factor B9.
XX
KW BMF; osteoporosis; fracture; cartilage; ss.
XX
OS Xenopus laevis.
XX
FH Key Location/Qualifiers
FT mat_peptide 651..1040
/*tag= a
/*product= BMP B9
XX
PN EP416578-A.
XX
XX 13-MAR-1991.
XX
XX 05-SEP-1990; 90EP-0117079.
XX
XX 20-JUL-1990; 90JP-0190774.
PR 06-SEP-1989; 89JP-0229250.
XX
PA (TAKE ) TAKEDA CHEMICAL IND KK.
PA (SCIT-) SCITECH RESEARCH CO.
XX
XX Murakami K, Ueno N, Kato Y;
XX
XX WPI: 1991-075112/11.
DR P-PSDB; AAR10990.
XX
XX Xenopus laevis bone morphogenetic protein and DNA encoding it -
PT used in therapy of fracture or osteoporosis
XX
XX Claim 5; Fig 2; 28pp; English.
XX
XX A Xenopus laevis liver-derived DNA library in Charon 28 vector, was
CC screened with a rat activin beta-A cDNA probe. Five clones were
CC isolated, including clone B9. They were subcloned in pUC19 and used
CC to transform competent E.coli HB101 cells. Transformant E.coli HB101/
CC pXar-9 coding for the B9 BMP was sequenced. See also AAQ10891-7.
XX
XX Sequence 1667 BP; 557 A; 295 C; 355 G; 450 T; 10 other;
SQ
Query Match 69.0%; Score 21.4; DB 12; Length 1667;
Best Local Similarity 80.6%; Pred. No. 12;
Matches 25; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 1 ATCATGTCCTCCTCGCTATCATGCCAACT 31
||||| ||||| ||||| ||||| ||||| |||||
Db 777 ATCATGACCCTCGCTATCATGCCAACT 807

RESULT 15
AAL07086
ID AAL07086 standard; DNA; 9662 BP.
XX
AC AAL07086;
XX
XX 21-NOV-2001 (first entry)
DT
```

XX Human reproductive system related antigen DNA SEQ ID NO: 9774.
DE
XX
XX Human; reproductive system related antigen; reproductive system disorder;
KW cancer; gene therapy; ds.
XX
XX Homo sapiens.
XX WO200155320-A2.
XX PD 02-AUG-2001.
XX
XX 17-JAN-2001; 2001WO-US01339.
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226686.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239355.
PR 13-OCT-2000; 2000US-0239357.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.

```

PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX PI Rosen CA, Barash SC, Ruben SM;
XX
XX DR WPI: 2001-465570/50.
XX
XX PT Isolated nucleic acid molecule encoding a reproductive system antigen
XX PT is used in preventing, treating or ameliorating a medical condition -
XX
XX PS Disclosure; SEQ ID NO 9774; 1297pp + Sequence Listing; English.
XX
XX CC The present invention provides the protein and coding sequences of a
XX CC number of human reproductive system related antigens. These can be used
XX CC in the prevention and treatment of reproductive system disorders,
XX CC including cancer. The present sequence is a genomic sequence encoding a
XX CC protein of the invention.
XX
XX SQ Sequence 9662 BP; 2746 A; 2172 C; 2097 G; 2647 T; 0 other;

Query Match 66.5%; Score 20.6; DB 22; Length 9662;
Best Local Similarity 85.2%; Pred. No. 36;
Matches 23; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 3 CATGGCTCCCTCTGGGCTATCATGCCAA 29
   ||| ||||| ||||| || |||||
Db 9175 CATGGCTCCCTCTGGGCTCTCTGCCAA 9201

```

Search completed: March 11, 2003, 00:17:27
Job time : 149.984 secs